Fate Therapeutics, Inc. announced that in connection with the company's restructuring plan and reduction to its workforce, the employment of Mark Plavsic, Ph.D., D.V.M., the Company's Chief Technical Officer, is expected to terminate effective as of March 6, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.08 USD | +4.62% | +0.49% | +9.09% |
May. 10 | Piper Sandler Adjusts Fate Therapeutics' Price Target to $4 From $7, Keeps Neutral Rating | MT |
May. 10 | Wedbush Adjusts Fate Therapeutics' Price Target to $5 From $7, Keeps Neutral Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.09% | 464M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- FATE Stock
- News Fate Therapeutics, Inc.
- Fate Therapeutics, Inc. Expects to Terminate Mark Plavsic as Chief Technical Officer, Effective as of March 6, 2023